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Introduction: Thoracoscopic or video-assisted thoracic esophage-
ctomies have been performed for the last 10 years. Nevertheless,
some reports have showed a risk of dissemination with endoscopic
or video-assisted surgery for malignant disease. This institute expe-
rienced three cases of port site recurrence after a thoracoscopic
esophagectomy for advanced esophageal cancer. Following those
cases, induction chemo-radiation therapy was performed for patient
with advanced esophageal cancer before thoracoscopic or video-
assisted esophagectomy. Since introducing induction chemo-radia-
tion therapy, no patients have experienced port site recurrence after
a thoracoscopic or video-assisted esophagectomy for advanced
esophageal cancer. In this study, the two patients groups are com-
pared before and after the introduction of induction chemo-radiation
therapy.
Patients and Methods: Between November 1995 and December
2005, thoracoscopic and video-assisted esophagectomies were per-
formed on 112 (72.7%) patients out of 154 who underwent a surgical
resection for thoracic and abdominal esophageal cancer. The histo-
logic type of cancer was squamous cell carcinoma in 109 (97.4%)
patients and adenocarcinoma in 3 (2.6%). Ninety-one patients were
men and 21 were women. The tumor was located in the upper
thoracic esophagus in 22 (19.6%) patients, the middle thoracic
esophagus in 49 (43.8%), the lower thoracic esophagus in 34
(30.4%), and the abdominal esophagus in 7 (6.2%).
Results: Before December 1999, port site recurrence occurred in
three cases of those of 29 patients with clinical T2–T4 esophageal
cancer from 3 to 6 months after surgery, and pleural dissemination
was observed in two of those patients. Since January 2000, induction
chemo-radiation therapy (low-dose fluorouracil and platinum  40
Gy radiation) has been performed to 31 patients with clinical T2–T4
disease, and port site recurrence has not occurred in any patients
who received trimodality therapy.
Conclusions: We think that the trend toward less port site recurrences
with induction therapy should be examined in future studies of video-
assisted thoracic surgery esophagectomy to confirm our findings.
Key Words: Thoracoscopic esophagectomy, Esophageal cancer,
Induction therapy, Port site recurrence.
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Thoracoscopic or video-assisted thoracic surgery esoph-agectomies have been performed routinely over the last
10 years.1–2 Nevertheless, some reports showed a risk of
dissemination with endoscopic or video-assisted surgery for
malignant disease.3–5 This institute experienced three cases of
port site recurrence after a thoracoscopic esophagectomy for
advanced esophageal cancer. Following those cases, induc-
tion chemo-radiation therapy was performed for patients with
advanced esophageal cancer before thoracoscopic or video-
assisted esophagectomy. Since introducing induction chemo-
radiation therapy, no patients have experienced port site
recurrence after a thoracoscopic or video-assisted esopahgec-
tomy for advanced esophageal cancer. In this study, the two
patients groups are compared before and after introducing
induction chemo-radiation therapy.
PATIENTS AND METHODS
The criteria for performing a thoracoscopic and video-
assisted esophagectomy for patient selection were (1) tumor
limited to the esophageal wall, (2) no previous history of the
right side major thoracic surgery, and (3) the patients ability
to tolerate left side single-lung ventilation. Between Novem-
ber 1995 and December 2005, thoracoscopic and video-
assisted esophagectomies were performed on 112 (72.7%)
patients out of 154 who underwent surgical resection for
thoracic and abdominal esophageal cancer. The histologic
type of cancer was squamous cell carcinoma in 109 (97.4%)
patients and adenocarcinoma in 3 (2.6%). The ages of the
patients ranged from 40 to 79 years; mean 63  9 years.
These patients included 91 (81.2%) men and 21 (18.8%)
women. The tumor was located in the upper thoracic esoph-
agus in 22 (19.6%) patients, the middle thoracic esophagus in
49 (43.8%), the lower thoracic esophagus in 34 (30.4%), and
the abdominal esophagus in 7 (6.2%).
Department of Surgery II, Oita University Faculty of Medicine; and Depart-
ment of Thoracic Surgery, Fukuoka University School of Medicine,
Fukuoka, Japan.
Disclosure: The authors declare no conflicts of interest.
Address for correspondence: Satoshi Yamamoto, PhD, Department of Surgery
II, Oita University Faculty of Medicine, Jonan-ku Nanakuma 7-45-1, 814-
0180 Fukuoka, Japan. E-mail: s-yamamoto@med.oita-u.ac.jp
Copyright © 2008 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/09/0401-0131
Journal of Thoracic Oncology • Volume 4, Number 1, January 2009 131
Induction Chemo-Radiation Therapy
From January 2000, induction chemo-radiation therapy
was performed in 31 patients suspected to have a T2–T3
esophageal tumor detected by computed tomography (CT)
scan and endoscopic ultrasonography. The radiotherapy was
administered in 1.5 Gy fractions 6 days a week for 27 days.
The 5-fluorouracil was given as a continuous infusion of 250
mg/body/d for 20 days along with the radiotherapy. One-hour
infusion therapy for cisplatin was administered at a dose of 10
mg/body for 20 days along with the radiotherapy.
The induction chemo-radiation group with 31 patients
of clinical T2–T3 esophageal cancer treated after 2000 was
compared with the group of 29 patients without induction
chemo-radiation treated from November 1995 to December
1999.
Surgical Procedures
The technique for a thoracoscopic and video-assisted
esophagectomy has been described previously.1 It usually in-
duced three fields (neck, thoracic, and abdominal) lymph node
dissection for the patients with esophageal cancer. The patients
were placed in the left decubitus position, and left lung ventila-
tion was initiated. Five or six thoracic ports for thoracoscopic
devices were inserted from the fourth to eighth intercostal spaces
in the anterior, middle, and posterior axillary lines. A 30-degree
visual thoracoscope was then inserted through the port placed in
the seventh intercostal space at the midaxillary line. The thoracic
esophagus and mediastinal nodes were dissected with a har-
monic scalpel (Ethicon Endo-Surgery, Cincinnati, OH). Lymph
nodes along the left recurrent laryngeal nerve were dissected
with bipolar electric coagulator scissors to prevent heat injury to
the nerve. After a total dissection of the thoracic esophagus, the
esophagus was then divided at upper thorax. After insertion of a
thoracic drainage tube, the patient was placed in the supine
position. A collar incision in the neck and an 8-cm upper-median
abdominal incision were made, and the surgeon used a head-
lamp to illuminate the peritoneal cavity. Bilateral neck and
abdominal lymph node dissection was performed. The dissec-
tion of the lower thoracic and abdominal esophagus was per-
formed via the transhiatal route. The esophagus was pulled into
the abdominal cavity. A gastric tube was made and pulled up
through the retrosternal route then it was anastomosed end-to-
end to the cervical esophagus with 4-0 monofilament absolvable
sutures.
RESULTS
The overall 5-year survival rate was 52% (Figure 1).
All patients with stage 0 disease were alive after 5 years. The
5-year survival rate was 87% in stage I disease, 70% in stage
IIA disease, 68% in stage IIB disease, and 27% in stage III
disease (Figure 2). There were no patients with stage IV
disease who survived 4 years or longer (Figure 2). The 5-year
survival rate of patients with node-negative disease was 75%,
and for those with node-positive disease it was 31%.
The patient characteristics of the induction chemo-
radiation group and noninduction chemo-radiation group are
shown in Table 1. There is no significant difference between
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FIGURE 1. Overall survival of patients undergoing a thora-
coscopic esophagectomy for esophageal cancer.
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FIGURE 2. Overall survival by pathologic stage of the pa-
tients undergoing a thoracoscopic esophagectomy for
esophageal cancer.
TABLE 1. Patient’s Characteristics of Both Groups
Noninduction Group,
n  29
(1995–1999)
Induction Group,
n  31
(2000–2005) p
Age (yr) 60.8  9.8 59.2  7.9
Gender (male/female) 24/5 23/8
Squamous cell
carcinoma
28 31 0.483
Adenocarcinoma 1 0
Upper thoracic 4 6
Middle thoracic 12 12 0.981
Lower thoracic 10 11
Abdonimal 3 2
c-T2 6 7
c-T3 17 22 0.269
c-T4 6 2
c-NO 7 11 0.405
c-Ni 22 20
Port site recurrence 3 0 0.101
Pathologic response of
induction therapy
Grade 1a 13
Grade 1b 2
Grade 2 12
Grade 3 4
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both groups in age, gender, pathologic differentiation, tumor
location, and clinical disease staging.
Port site recurrence occurred in three patients from 3 to
6 months after surgery, and two patients experienced simul-
taneous pleural dissemination. All of those patients under-
went a thoracoscopic esophagectomy between November
1995 and November 1999, and they had not received induc-
tion chemo-radiation therapy. The pathologic stage of the
patient was T2N1M0 stage III, T3N1M0 stage III, and
T3N1M1B stage IVB disease. These three patients underwent
chest wall resection or tumor extraction and chemotherapy or
radiation therapy for recurrent disease. They died of pleuritis
carcinomatosa and lung metastasis 211, 353, and 798 days,
respectively, after the esophagectomy. Since January 2000,
induction chemo-radiation therapy has been performed for
patients with clinical T2–T4 disease, and port site recurrence
has not occurred in patients who received trimodality therapy.
Case
Case 1 was a 50-year-old man with squamous cell
carcinoma of the esophagus. A barium swallow showed an
irregular stricture of the middle thoracic esophagus, and
endoscopy showed a tumor stricture extending between 27
and 31 cm from the incisors. A CT scan confirmed the
presence of a mass of the middle thoracic esophagus, sepa-
rated from the tracheo-bronchial tree and the aorta and no
evidence of distant metastasis. The patient underwent a video-
assisted esophagectomy and gastric tube reconstruction via
the retro-sternal route. The postoperative course was unevent-
ful and the patient recovered well from the procedure. An
esophagogram performed on the seventh postoperative day
showed a patent esophago-gastric tube anastomosis and the
absence of leaks, and the patient resumed oral feeding with a
soft diet. The pathologic examination of the resected speci-
men confirmed a well differentiated squamous cell carcinoma
infiltrating the layer of the proper muscle of the esophagus
and cervical, paratracheal, and abdominal nodal metastasis
(p-T2N1M1a). Three months after surgery, two 2 cm subcuta-
neous masses were evident in two port sites of the five port
sites of video-assisted thoracotomy. A biopsy under local
anesthesia revealed metastatic squamous cell carcinoma. A
CT scan showed pleural thickness and dissemination. The
patient had radiation therapy to the right pleural cavity;
however, the patient died with multiple lung metastasis and
pleuraitis carcinomatosa at 211 days after esophagectomy
(Table 2).
Case 2 was a 59-year-old man with squamous cell
carcinoma of the esophagus. A barium swallow showed an
irregular stricture of the lower thoracic esophagus, and an
endoscopy showed a tumor stricture at 30 cm from the
incisors, and the endoscope could not go through to the anal
side of the tumor. A CT scan confirmed the presence of a
mass of the middle thoracic esophagus, separated from the
tracheo-bronchial tree and the aorta and no evidence of
distant metastasis. The patient underwent a video-assisted
esophagectomy and gastric tube reconstruction via the retro-
sternal route. The postoperative course was uneventful and
patient recovered well from the procedure. An esophagogram
performed on the seventh postoperative day showed a patent
esophago-gastric tube anastomosis and the absence of leaks,
and the patient resumed oral feeding with a soft diet. The
pathologic examination of the resected specimen confirmed
a moderately differentiated squamous cell carcinoma infil-
trating the muscle layer of the esophagus and paratracheal
and abdominal nodal metastasis (p-T3N1M0). Four
months after surgery, a 3-cm subcutaneous mass was
evident in a port site of the five port sites of video-assisted
thoracotomy. A biopsy under local anesthesia revealed
metastatic squamous cell carcinoma. A CT scan showed
local pleural thickness. The patient had a right chest wall
resection with IV–IX rib resection; however, the patient
died as a result of pleuraitis carcinomatosa at 353 days
after the esophagectomy.
Case 3 was a 59-year-old man with squamous cell
carcinoma of the esophagus. A barium swallow showed an
irregular stricture of the abdominal esophagus, and an endos-
copy showed a tumor stricture at 35 cm from the incisors. A
CT scan confirmed the presence of a mass of the abdominal
esophagus with paratracheal lymph node metastasis. The
patient underwent a video-assisted esophagectomy and gas-
tric tube reconstruction via the retro-sternal route. The post-
operative course was uneventful and the patient recovered
well from the procedure. An esophagogram performed on the
seventh postoperative day showed a patent esophago-gastric
tube anastomosis and the absence of leaks, and the patient
resumed oral feeding with a soft diet. The pathologic exam-
ination of the resected specimen confirmed a moderately
differentiated squamous cell carcinoma infiltrating over the
muscle layer of the esophagus and paratracheal and abdom-
inal nodal metastasis (p-T4N1M1a). Six months after sur-
gery, a 3-cm subcutaneous mass was evident in a port site of
the five port sites of video-assisted thoracotomy. A biopsy
under local anesthesia revealed metastatic squamous cell
carcinoma. A CT scan showed a 30 mm mass in the middle
mediastinum. The patient had a radiation therapy for 60 Gy
for the mediastinum and 30 Gy for the right chest wall, and
the patient demonstrated a partial response. The patient died
of pleuraitis carcinomatosa at 798 days after the esophagec-
tomy.
TABLE 2. Cases of Recurrence
Cases 50-yr-Old (Male) 59-yr-Old (Male) 48-yr-Old (Male)
T factor p-T2 p-T3 p-T4
N factor p-N1 p-N1 p-N1
M factor p-M1a p-M0 p-M1a
Tumor location Middle thoracic Lower thoracic Abdominal
esophagus
Interval of port
site
recurrence
3 mo 4 mo 6 mo
Therapy Port site resection
 radiation (40
Gy)
Port site resection

chemotherapy
(UFT)
Port site resection
 radiation (60
Gy)
Prognosis 211 d died 353 d died 798 d died
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DISCUSSION
Thoracoscopic or laparoscopic surgery has been
spreading worldwide over the last decade. Several surgical
approaches have been performed using a thoracoscope or
laparoscope for several malignant diseases. Therefore, there
have been some reports of port site recurrence of laparoscopic
surgery for abdominal malignancies,3,4 and some reports of
dissemination of malignant tumors after video-assisted tho-
racic surgery.5 Nevertheless, there are few reports of port site
recurrence of the thoracoscopic or video-assisted surgery for
esophageal cancer.6–9
Thoracoscopic or video-assisted esophagectomy has
been used in this institute for T1–T3 esophageal cancer. The
outcome of the thoracoscopic or video-assisted esophagec-
tomy for the early stage esophageal cancer of T1–T2 is good.2
Nevertheless, three patients demonstrated port site recurrence
of clinical T3 esophageal cancer.
There are some theories of the port site recurrence of
endoscopic surgery for malignant disease.10,11 A “gchimney
theory” was described in a literature,12 that is the high
gradient subsequent outflow of floating tumor cells through
the port wound, which does not occur in a thoracotomy
wound.
Induction therapy for esophageal cancer has been per-
formed for many years.13–16 Some reports show evidence of
the efficacy of induction therapy for advanced esophageal
squamous cell carcinoma.17,18 Hsu et al.18 showed a pro-
longed survival rate for patients with esophageal cancer after
induction therapy using daily low dose cisplatin and contin-
uous 5-fluorouracil. Therefore, induction chemotherapy using
low dose cisplatin and continuous 5-fiuorouracil, in combi-
nation with 40 Gy radiation therapy has been administered to
patients with esophageal cancer before a thoracoscopic or
video-assisted esophagectomy since 2000. As a result, none
of those patients have experienced port site recurrence.
CONCLUSIONS
We think that the trend toward less port site recurrences
with induction therapy should be examined in future studies
of VATS esophagectomy to confirm our findings.
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